EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors

Por Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Weichel, Michael, Gantke, Thorsten, Knackmuss, Stefan, Molkenthin, Vera, Marschner, Jens-Peter, Treder, Martin
Publicado no J Immunother Cancer (2015)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Por Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Knackmuss, Stefan, Weichel, Michael, Gantke, Thorsten, Molkenthin, Vera, Zhukovsky, Eugene A., Tesar, Michael, Treder, Martin
Publicado no Front Oncol (2017)

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

Por Reusch, Uwe, Duell, Johannes, Ellwanger, Kristina, Herbrecht, Carmen, Knackmuss, Stefan HJ, Fucek, Ivica, Eser, Markus, McAleese, Fionnuala, Molkenthin, Vera, Le Gall, Fabrice, Topp, Max, Little, Melvyn, Zhukovsky, Eugene A
Publicado no MAbs (2015)